Foundayo (Orforglipron) Explained: The New Daily GLP-1 Pill with No Food Restrictions
Foundayo is the newest of the three FDA-approved oral GLP-1 medications, and the only one built from a completely different kind of molecule than the others. Here's what it is, what the trial data actually shows, and how its pricing works.
What Makes Foundayo Different
Foundayo's active ingredient, orforglipron, is a small, non-peptide molecule — a fundamentally different chemical approach than semaglutide or tirzepatide, both of which are peptides. That distinction isn't just academic: because orforglipron is small enough to absorb through the gut the way conventional pills do, it doesn't need SNAC or any other permeation-enhancer technology. Practically, that means Foundayo is the only oral GLP-1 you can take at any time of day, with or without food or water — no empty-stomach requirement, no 30-minute waiting window before your morning coffee.
It's approved specifically for chronic weight management in adults with obesity or overweight plus at least one weight-related health condition. As of this writing, it is not approved for type 2 diabetes, though a companion diabetes trial (ACHIEVE-1) has already reported results.
The Trial Data: ATTAIN-1
Foundayo's approval rests primarily on ATTAIN-1, a 72-week Phase 3 trial of over 3,100 adults with obesity or overweight. At the highest tested dose (36mg), the trial's efficacy estimand showed 11.2% mean weight loss, against 2.1% for placebo — with 54.6% of patients achieving at least 10% weight loss and 18.4% reaching 20% or more. Lilly's own press release cited a slightly higher 12.4% figure for the same dose using a different statistical estimand; both numbers describe the same trial, just counted differently, so don't be surprised if you see both cited elsewhere.
On safety, discontinuation due to adverse events rose with dose: 5.1%, 7.7%, and 10.3% across the three active-dose groups, compared to 2.6% on placebo. The most common side effects were the familiar GLP-1 lineup — nausea, constipation, diarrhea, vomiting, and dyspepsia. One notable safety win: Phase 3 data showed no significant liver enzyme elevations, clearing a hurdle that has sunk other small-molecule GLP-1 candidates in development (Pfizer discontinued its own oral candidate, lotiglipron, over liver safety signals).
The Maintenance Question: What ATTAIN-MAINTAIN Showed
A companion trial, ATTAIN-MAINTAIN, tested something practically important: can patients who already lost weight on an injectable pen switch to Foundayo and keep the results? Patients who'd lost weight on Wegovy or Zepbound were randomized to switch to orforglipron or placebo. Those coming from Wegovy regained only about 0.9 kg on average; those coming from Zepbound regained about 5.0 kg. Both groups did meaningfully better than placebo, and it's the basis for a "step-down" model some providers are starting to use — injectable for the initial loss, Foundayo pill for maintenance.
Pricing
| Dose | LillyDirect Self-Pay Price |
|---|---|
| 0.8 mg (starting dose) | $149/mo |
| 2.5 mg | $199/mo |
| 5.5 / 9 / 14.5 / 17.2 mg | $299/mo (Self-Pay Journey Program) or $349/mo |
| Commercially insured (with coverage) | $25/mo |
| Medicare Part D | $50/mo (effective July 1, 2026) |
The dose-tiered structure means your actual cost depends heavily on where you land in your titration schedule — the $149 starting price is real, but most patients titrate up to the higher-dose, higher-price tiers over time as they approach a therapeutic dose.
What to Watch
The FDA requested additional post-market cardiac and liver safety data from Lilly shortly after approval — this is a standard post-approval monitoring request, not a withdrawal or label change, but it's worth knowing the agency is continuing to watch this specific safety profile as more patients use the drug in the real world.
Bottom Line
Foundayo is the most convenient oral GLP-1 on the market — no dosing ritual, no timing restrictions — with solid trial data (11–12% weight loss at 72 weeks) and a real, published maintenance-switch use case. It sits a bit below high-dose oral semaglutide's best published numbers and further below injectable tirzepatide's ceiling, but for anyone who wants an FDA-approved pill without the empty-stomach rules, it's currently the only option built specifically to skip them. For the fuller picture against its two main alternatives, see our Foundayo vs. Wegovy pill vs. compounded comparison.